<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677725</url>
  </required_header>
  <id_info>
    <org_study_id>NEAT</org_study_id>
    <nct_id>NCT04677725</nct_id>
  </id_info>
  <brief_title>NEtwork to Control ATherothrombosis (NEAT Registry)</brief_title>
  <acronym>NEAT</acronym>
  <official_title>Brazilian Registry of Atherothrombotic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital do Coracao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Coracao</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NEAT is an observational cohort (Prospective registry of real world data) of patients with&#xD;
      coronary and peripheral artery disease in an outopatient setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      National multicenter registry in Brazil with initial plan of 25 sites from the 5 Brazilian&#xD;
      regions. It will be coordinated by HCOR Research Institute which will perform regulatory,&#xD;
      data and site management beyond academic leadership.NEAT is an observational cohort&#xD;
      (Prospective registry of real world data) of patients with coronary and peripheral artery&#xD;
      disease in an outopatient setting with 12 months of follow-up with collection of data at&#xD;
      baseline, 6 months and 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Percentage of patients receiving evidence based therapies to reduce cardiovascular risk</measure>
    <time_frame>Baseline</time_frame>
    <description>DOMAIN 1: Appropriate use of antithrombotic therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients receiving evidence based therapies to reduce cardiovascular risk</measure>
    <time_frame>Baseline</time_frame>
    <description>DOMAIN 2: Cholesterol control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients receiving evidence based therapies to reduce cardiovascular risk</measure>
    <time_frame>Baseline</time_frame>
    <description>DOMAIN 3: Blood pressure control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients receiving evidence based therapies to reduce cardiovascular risk</measure>
    <time_frame>Baseline</time_frame>
    <description>DOMAIN 4: Glycemic control / diabetes treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients receiving evidence based therapies to reduce cardiovascular risk</measure>
    <time_frame>Baseline</time_frame>
    <description>DOMAIN 5: Weight control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients receiving evidence based therapies to reduce cardiovascular risk</measure>
    <time_frame>Baseline</time_frame>
    <description>DOMAIN 6: Non-pharmacological intervention: In this domain, there are 2 items to be evaluated: 1) No smoking; 2) Physical exercise ≥ 150 minutes per week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients receiving complete evidence based therapies to reduce cardiovascular risk</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Patient should receive all of the following to consider complete evidence based therapy: Appropriate use of antithrombotic therapy; Cholesterol control; Blood pressure control; Glycemic control / diabetes treatment; Weight control; Non-pharmacological intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with complete control of risk factors (blood pressure, cholesterol and glycemia)</measure>
    <time_frame>baseline, 06 and 12 months</time_frame>
    <description>blood pressure, cholesterol and glycemia levels at baseline, 06 and 12 months</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Atherothrombosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with coronary and peripheral arterial disease in an outpatient setting&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients ≥45 years followed in ambulatory setting with ≥1 of the following 3 criteria:&#xD;
&#xD;
          1. Documented coronary disease (≥1 criteria must apply):&#xD;
&#xD;
               -  Stable angina&#xD;
&#xD;
               -  History of Unstable Angina&#xD;
&#xD;
               -  History of coronary angioplasty/stenting&#xD;
&#xD;
               -  History of coronary artery bypass graft&#xD;
&#xD;
               -  Myocardial infarction within the last 20 years&#xD;
&#xD;
          2. Documented symptomatic Peripheral Arterial Disease (≥1 criteria must apply):&#xD;
&#xD;
               -  Previous aorto-femoral bypass surgery, limb bypass surgery, or percutaneous&#xD;
                  transluminal angioplasty revascularization of the iliac, or infra-inguinal&#xD;
                  arteries, or&#xD;
&#xD;
               -  Previous limb or foot amputation for arterial vascular disease, or&#xD;
&#xD;
               -  History of intermittent claudication and one or more of the following: 1) An&#xD;
                  ankle/arm blood pressure (BP) ratio &lt; 0.90, or 2) Significant peripheral artery&#xD;
                  stenosis (≥50%) documented by angiography, or by duplex ultrasound.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients from institutions that don't provide the Institutional Authorization Term,&#xD;
&#xD;
          -  Incapacity of follow-up in one year according to investigator judgment (severe&#xD;
             neuropsychiatric condition, life expectancy &lt; 12 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro de Barros e Silva, MD, MHS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro de Barros e Silva, MD, MHS, PhD</last_name>
    <phone>+551130656611</phone>
    <email>pgmelo@hcor.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Flavia Kojima</last_name>
    <phone>+551130656611</phone>
    <email>fkojima@hcor.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Do Coração</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05410001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PEDRO GABRIEL MELO DE BARROS E SILVA, MD, MHS, PHD</last_name>
      <phone>55113053-6611</phone>
      <email>pedro.barros@bcri.org.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

